Visceral leishmaniasis and HIV coinfection: current perspectives
- PMID: 30410407
- PMCID: PMC6197215
- DOI: 10.2147/HIV.S143929
Visceral leishmaniasis and HIV coinfection: current perspectives
Abstract
Visceral leishmaniasis (VL) is caused by Leishmania donovani and Leishmania infantum. The burden of VL is concentrated in tropical and subtropical areas; however, HIV infection has spread VL over a hyperendemic area. Several outcomes are observed as a result of VL-HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response. Concerning clinical manifestation, typical and unusual manifestation has been observed during active VL in HIV-infected patient, as well as alteration in immunoresponse, inducing greater immunosuppression by low CD4 T-lymphocyte count or even by induction of immunoactivation, with cell senescence. Serological diagnosis of VL in the HIV-infected is poor, due to low humoral response, characterized by antibody production, so parasitological methods are more recommended. Another important and even more challenging point is the definition of the best therapeutic regimen for VL in HIV-coinfected patients, because in this population there is greater failure and consequently higher mortality. The challenge of better understanding immunopathogenesis in order to obtain more effective therapies is one of the crucial points to be developed. The combination of drugs and the use of secondary prophylaxis associated with highly active antiretroviral therapy may be the best tool for treatment of HIV coinfection. Some derivatives from natural sources have action against Leishmania; however, studies have been limited to in vitro evaluation, without clinical trials.
Keywords: AIDS; HIV infection; diagnosis; therapeutic response; visceral leishmaniasis.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Similar articles
-
Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context.PLoS Negl Trop Dis. 2020 Apr 23;14(4):e0008253. doi: 10.1371/journal.pntd.0008253. eCollection 2020 Apr. PLoS Negl Trop Dis. 2020. PMID: 32324738 Free PMC article.
-
Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.Acta Trop. 2017 Aug;172:186-191. doi: 10.1016/j.actatropica.2017.05.011. Epub 2017 May 10. Acta Trop. 2017. PMID: 28501450
-
New world Leishmania spp. infection in people living with HIV: Concerns about relapses and secondary prophylaxis.Acta Trop. 2021 Dec;224:106146. doi: 10.1016/j.actatropica.2021.106146. Epub 2021 Sep 23. Acta Trop. 2021. PMID: 34562423
-
Visceral leishmaniasis and HIV coinfection in Latin America.PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3136. doi: 10.1371/journal.pntd.0003136. eCollection 2014 Sep. PLoS Negl Trop Dis. 2014. PMID: 25233461 Free PMC article. Review.
-
Visceral leishmaniasis and HIV coinfection in the Mediterranean region.PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3021. doi: 10.1371/journal.pntd.0003021. eCollection 2014 Aug. PLoS Negl Trop Dis. 2014. PMID: 25144380 Free PMC article. Review.
Cited by
-
Shared challenges to the control of complex intracellular neglected pathogens.Front Public Health. 2024 Sep 11;12:1423420. doi: 10.3389/fpubh.2024.1423420. eCollection 2024. Front Public Health. 2024. PMID: 39324165 Free PMC article. Review.
-
VL-HIV co-infection with Leishmania containing skin lesions resembling para-kala-azar dermal leishmaniasis.PLoS Negl Trop Dis. 2024 Aug 26;18(8):e0012438. doi: 10.1371/journal.pntd.0012438. eCollection 2024 Aug. PLoS Negl Trop Dis. 2024. PMID: 39186781 Free PMC article.
-
Serological Screening and Risk Factors Associated with Leishmania infantum Positivity in Newly Diagnosed HIV Patients in Greece.Microorganisms. 2024 Jul 10;12(7):1397. doi: 10.3390/microorganisms12071397. Microorganisms. 2024. PMID: 39065165 Free PMC article.
-
Seroprevalence of visceral leishmaniasis among pregnant women in Jahrom city in Fars province, southern Iran.Parasite Epidemiol Control. 2024 Apr 16;25:e00349. doi: 10.1016/j.parepi.2024.e00349. eCollection 2024 May. Parasite Epidemiol Control. 2024. PMID: 38645673 Free PMC article.
-
The spleen is the graveyard of CD4+ cells in patients with immunological failure of visceral leishmaniasis and AIDS.Parasit Vectors. 2024 Mar 15;17(1):132. doi: 10.1186/s13071-024-06151-6. Parasit Vectors. 2024. PMID: 38491526 Free PMC article.
References
-
- World Health Organization [webpage on the Internet] Leishmaniasis. 2018. [Accessed March 31, 2018]. Available from: http://www.who.int/news-room/fact-sheets/detail/leishmaniasis.
-
- World Heath Organization . Control of the Leishmaniases. Geneva: WHO; 2010.
-
- World Health Organization [webpage on the Internet] HIV/AIDS. 2018. [Accessed March 31, 2018]. Available from: http://www.who.int/news-room/fact-sheets/detail/hiv-aids.
-
- World Heath Organization . Manual on Case Management and Surveillance of the Leishmaniases in the WHO European Region. Geneva: WHO; 2017.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials